{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T07:25:09Z","timestamp":1771658709804,"version":"3.50.1"},"reference-count":69,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.hoc.2021.03.008","type":"journal-article","created":{"date-parts":[[2021,5,27]],"date-time":"2021-05-27T11:12:23Z","timestamp":1622113943000},"page":"793-806","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Treatment of Chronic Lymphocytic Leukemia After Discontinuation of Bruton\u2019s Tyrosine Kinase Inhibitors"],"prefix":"10.1016","volume":"35","author":[{"given":"Meghan C.","family":"Thompson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony R.","family":"Mato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.hoc.2021.03.008_bib1","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","author":"Byrd","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.hoc.2021.03.008_bib2","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1509981","article-title":"Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia","volume":"374","author":"Byrd","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"25","key":"10.1016\/j.hoc.2021.03.008_bib3","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia","volume":"373","author":"Burger","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.hoc.2021.03.008_bib4","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/s41375-019-0602-x","article-title":"Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL\/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study","volume":"34","author":"Burger","year":"2020","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.hoc.2021.03.008_bib5","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1002\/ajh.25638","article-title":"Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma","volume":"94","author":"Munir","year":"2019","journal-title":"Am J Hematol"},{"issue":"10","key":"10.1016\/j.hoc.2021.03.008_bib6","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/S1470-2045(16)30212-1","article-title":"Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study","volume":"17","author":"O'Brien","year":"2016","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2021.03.008_bib7","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S1470-2045(14)71182-9","article-title":"Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial","volume":"16","author":"Farooqui","year":"2015","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.hoc.2021.03.008_bib8","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1056\/NEJMoa1817073","article-title":"Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia","volume":"381","author":"Shanafelt","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"26","key":"10.1016\/j.hoc.2021.03.008_bib9","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1812836","article-title":"Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL","volume":"379","author":"Woyach","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.hoc.2021.03.008_bib10","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1470-2045(18)30788-5","article-title":"Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"Moreno","year":"2019","journal-title":"Lancet Oncol"},{"issue":"10232","key":"10.1016\/j.hoc.2021.03.008_bib11","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/S0140-6736(20)30262-2","article-title":"Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial","volume":"395","author":"Sharman","year":"2020","journal-title":"Lancet"},{"issue":"15","key":"10.1016\/j.hoc.2021.03.008_bib12","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1182\/blood.2018884940","article-title":"Acalabrutinib monotherapy in patients with relapsed\/refractory chronic lymphocytic leukemia: updated phase 2 results","volume":"135","author":"Byrd","year":"2020","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.hoc.2021.03.008_bib13","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1200\/JCO.19.03355","article-title":"ASCEND: Phase III, randomized trial of acalabrutinib versus idelalisib plus rituximab or bendamustine plus rituximab in relapsed or refractory chronic lymphocytic leukemia","volume":"38","author":"Ghia","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.hoc.2021.03.008_bib14","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1056\/NEJMc2005943","article-title":"Ibrutinib for chronic lymphocytic leukemia with TP53 alterations","volume":"383","author":"Ahn","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hoc.2021.03.008_bib15","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2020.259432","article-title":"Zanubrutinib monotherapy for patients with treatment na\u00efve chronic lymphocytic leukemia and 17p deletion","author":"Tam","year":"2020","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.hoc.2021.03.008_bib16","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s13045-020-00884-4","article-title":"Treatment of relapsed\/refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study","volume":"13","author":"Xu","year":"2020","journal-title":"J\u00a0Hematol Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2021.03.008_bib17","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1001\/jamaoncol.2014.218","article-title":"Etiology of Ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia","volume":"1","author":"Maddocks","year":"2015","journal-title":"JAMA Oncol"},{"issue":"5","key":"10.1016\/j.hoc.2021.03.008_bib18","doi-asserted-by":"crossref","first-page":"874","DOI":"10.3324\/haematol.2017.182907","article-title":"Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis","volume":"103","author":"Mato","year":"2018","journal-title":"Haematologica"},{"issue":"13","key":"10.1016\/j.hoc.2021.03.008_bib19","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1200\/JCO.2016.70.2282","article-title":"BTK(C481S)-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia","volume":"35","author":"Woyach","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"10.1016\/j.hoc.2021.03.008_bib20","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1002\/cncr.30596","article-title":"Long-term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib","volume":"123","author":"Jain","year":"2017","journal-title":"Cancer"},{"issue":"18","key":"10.1016\/j.hoc.2021.03.008_bib21","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1182\/blood-2016-05-716977","article-title":"Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience","volume":"128","author":"Mato","year":"2016","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.hoc.2021.03.008_bib22","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.1182\/blood.V126.23.2945.2945","article-title":"Outcomes of patients with relapsed\/refractory chronic lymphocytic leukemia after ibrutinib discontinuation outside clinical trials: a single institution experience","volume":"126","author":"Sandoval-Sus","year":"2015","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.hoc.2021.03.008_bib23","doi-asserted-by":"crossref","first-page":"e208","DOI":"10.3324\/haematol.2018.198820","article-title":"Long-term real-world results of ibrutinib therapy in patients with relapsed or refractory chronic lymphocytic leukemia: 30-month follow up of the Swedish compassionate use cohort","volume":"104","author":"Winqvist","year":"2019","journal-title":"Haematologica"},{"issue":"12","key":"10.1016\/j.hoc.2021.03.008_bib24","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.3324\/haematol.2016.147900","article-title":"Ibrutinib for relapsed\/refractory chronic lymphocytic leukemia: a UK and Ireland analysis of outcomes in 315 patients","volume":"101","author":"Forum","year":"2016","journal-title":"Haematologica"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2021.03.008_bib25","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1182\/blood-2020-139951","article-title":"Dose reductions and discontinuations with chronic lymphocytic leukemia (CLL) patients receiving ibrutinib in community and academic settings","volume":"136","author":"Hou","year":"2020","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.hoc.2021.03.008_bib26","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1182\/bloodadvances.2018030007","article-title":"Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib","volume":"3","author":"Awan","year":"2019","journal-title":"Blood Adv"},{"issue":"15_suppl","key":"10.1016\/j.hoc.2021.03.008_bib27","doi-asserted-by":"crossref","first-page":"7530","DOI":"10.1200\/JCO.2019.37.15_suppl.7530","article-title":"Phase 2 study of acalabrutinib in ibrutinib (IBR)-intolerant patients (pts) with relapsed\/refractory (R\/R) chronic lymphocytic leukemia (CLL)","volume":"37","author":"Rogers","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"Supplement_1","key":"10.1016\/j.hoc.2021.03.008_bib28","doi-asserted-by":"crossref","first-page":"4311","DOI":"10.1182\/blood-2019-130062","article-title":"Toxicities and outcomes of acalabrutinib-treated patients with chronic lymphocytic leukemia: a retrospective analysis of real world patients","volume":"134","author":"Yazdy","year":"2019","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.hoc.2021.03.008_bib29","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1056\/NEJMoa1400029","article-title":"Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib","volume":"370","author":"Woyach","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"24","key":"10.1016\/j.hoc.2021.03.008_bib30","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1056\/NEJMc1402716","article-title":"Ibrutinib resistance in chronic lymphocytic leukemia","volume":"370","author":"Furman","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.hoc.2021.03.008_bib31","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1182\/blood-2016-06-719294","article-title":"Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia","volume":"129","author":"Ahn","year":"2017","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.hoc.2021.03.008_bib32","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/cncr.31831","article-title":"Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation","volume":"125","author":"Kanagal-Shamanna","year":"2019","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.hoc.2021.03.008_bib33","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1097\/PPO.0000000000000406","article-title":"Resistance mechanisms to targeted agents in chronic lymphocytic leukemia","volume":"25","author":"Kittai","year":"2019","journal-title":"Cancer J"},{"issue":"23","key":"10.1016\/j.hoc.2021.03.008_bib34","doi-asserted-by":"crossref","first-page":"6287","DOI":"10.1182\/blood-2011-01-328484","article-title":"Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765","volume":"117","author":"Herman","year":"2011","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.hoc.2021.03.008_bib35","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.ajhg.2012.08.006","article-title":"A\u00a0hypermorphic missense mutation in PLCG2, encoding phospholipase C\u03b32, causes a dominantly inherited autoinflammatory disease with immunodeficiency","volume":"91","author":"Zhou","year":"2012","journal-title":"Am J Hum Genet"},{"issue":"7","key":"10.1016\/j.hoc.2021.03.008_bib36","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1038\/leu.2017.110","article-title":"PLCG2 C2 domain mutations co-occur with BTK and PLCG2 resistance mutations in chronic lymphocytic leukemia undergoing ibrutinib treatment","volume":"31","author":"Jones","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2021.03.008_bib37","doi-asserted-by":"crossref","first-page":"11589","DOI":"10.1038\/ncomms11589","article-title":"Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition","volume":"7","author":"Burger","year":"2016","journal-title":"Nat Commun"},{"issue":"12","key":"10.1016\/j.hoc.2021.03.008_bib38","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1182\/bloodadvances.2016003632","article-title":"Clonal evolution underlying leukemia progression and Richter transformation in patients with ibrutinib-relapsed CLL","volume":"1","author":"Kadri","year":"2017","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.hoc.2021.03.008_bib39","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1182\/hematology.2020000168","article-title":"Approaches for relapsed CLL after chemotherapy-free frontline regimens","volume":"2020","author":"Roeker","year":"2020","journal-title":"Hematol Am Soc Hematol Education Program"},{"issue":"25","key":"10.1016\/j.hoc.2021.03.008_bib40","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"issue":"7574","key":"10.1016\/j.hoc.2021.03.008_bib41","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/nature15395","article-title":"Mutations driving CLL and their evolution in progression and relapse","volume":"526","author":"Landau","year":"2015","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.hoc.2021.03.008_bib42","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1080\/10428194.2019.1602268","article-title":"Rapid disease progression following discontinuation of ibrutinib in patients with chronic lymphocytic leukemia treated in routine clinical practice","volume":"60","author":"Hampel","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"10.1016\/j.hoc.2021.03.008_bib43","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1634\/theoncologist.2020-0388","article-title":"Disease flare during temporary interruption of ibrutinib therapy in patients with chronic lymphocytic leukemia","volume":"25","author":"Hampel","year":"2020","journal-title":"Oncologist"},{"issue":"17","key":"10.1016\/j.hoc.2021.03.008_bib44","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1182\/blood.2019002841","article-title":"How I manage CLL with venetoclax-based treatments","volume":"135","author":"Wierda","year":"2020","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.hoc.2021.03.008_bib45","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1182\/blood-2016-09-693598","article-title":"How I manage ibrutinib-refractory chronic lymphocytic leukemia","volume":"129","author":"Woyach","year":"2017","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2021.03.008_bib46","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S1470-2045(17)30909-9","article-title":"Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial","volume":"19","author":"Jones","year":"2018","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.hoc.2021.03.008_bib47","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.3324\/haematol.2018.193615","article-title":"Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States","volume":"103","author":"Mato","year":"2018","journal-title":"Haematologica"},{"issue":"14","key":"10.1016\/j.hoc.2021.03.008_bib48","doi-asserted-by":"crossref","first-page":"4264","DOI":"10.1158\/1078-0432.CCR-19-0361","article-title":"Tumor lysis, adverse events, and dose adjustments in 297 venetoclax-treated CLL patients in routine clinical practice","volume":"25","author":"Roeker","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.hoc.2021.03.008_bib49","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1093\/annonc\/mdx031","article-title":"Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients","volume":"28","author":"Mato","year":"2017","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.hoc.2021.03.008_bib50","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1111\/bjh.16271","article-title":"The efficacy and safety of venetoclax therapy in elderly patients with relapsed, refractory chronic lymphocytic leukaemia","volume":"188","author":"Eyre","year":"2020","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.hoc.2021.03.008_bib51","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1182\/blood.2018882555","article-title":"Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables","volume":"134","author":"Roberts","year":"2019","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.hoc.2021.03.008_bib52","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.hoc.2021.03.008_bib53","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1056\/NEJMoa1713976","article-title":"Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia","volume":"378","author":"Seymour","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.hoc.2021.03.008_bib54","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/S1470-2045(16)30019-5","article-title":"Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study","volume":"17","author":"Stilgenbauer","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.hoc.2021.03.008_bib55","series-title":"NCCN Guidlines: chronic lymphocytic leukemia\/small lymphocytic lymphoma","year":"2020"},{"issue":"11","key":"10.1016\/j.hoc.2021.03.008_bib56","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa1315226","article-title":"Idelalisib and rituximab in relapsed chronic lymphocytic leukemia","volume":"370","author":"Furman","year":"2014","journal-title":"N\u00a0Eng J Med"},{"issue":"16","key":"10.1016\/j.hoc.2021.03.008_bib57","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1200\/JCO.18.01460","article-title":"Final results of a randomized, phase III study of rituximab with or without idelalisib followed by open-label idelalisib in patients with relapsed chronic lymphocytic leukemia","volume":"37","author":"Sharman","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"23","key":"10.1016\/j.hoc.2021.03.008_bib58","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1182\/blood-2018-05-850461","article-title":"The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL\/SLL","volume":"132","author":"Flinn","year":"2018","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.hoc.2021.03.008_bib59","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.1158\/1078-0432.CCR-19-3815","article-title":"Assessment of the efficacy of therapies following venetoclax discontinuation in CLL Reveals BTK inhibition as an effective strategy","volume":"26","author":"Mato","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.hoc.2021.03.008_bib60","article-title":"Phase 2 Study of the safety and efficacy of Umbralisib in patients with CLL who are intolerant to BTK or PI3K\u03b4 inhibitor therapy","author":"Mato","year":"2020","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.hoc.2021.03.008_bib61","doi-asserted-by":"crossref","first-page":"3977","DOI":"10.1182\/bloodadvances.2020001956","article-title":"Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents","volume":"4","author":"Roeker","year":"2020","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.hoc.2021.03.008_bib62","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/s41409-018-0207-4","article-title":"Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT Chronic Malignancies and Lymphoma Working Parties","volume":"54","author":"Dreger","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2021.03.008_bib63","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1182\/blood-2020-140491","article-title":"Updated follow-up of patients with relapsed\/refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma treated with lisocabtagene maraleucel in the phase 1 monotherapy cohort of transcend CLL 004, including high-risk and ibrutinib-treated patients","volume":"136","author":"Siddiqi","year":"2020","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.hoc.2021.03.008_bib64","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1200\/JCO.2017.72.8519","article-title":"Durable molecular remissions in chronic lymphocytic leukemia treated with CD19-specific chimeric antigen receptor-modified t\u00a0cells after failure of ibrutinib","volume":"35","author":"Turtle","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2021.03.008_bib65","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1182\/blood-2020-140622","article-title":"Transcend CLL 004: Phase 1 Cohort of Lisocabtagene Maraleucel (liso-cel) in Combination with Ibrutinib for Patients with Relapsed\/Refractory (R\/R) Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma (CLL\/SLL)","volume":"136","author":"Wierda","year":"2020","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.hoc.2021.03.008_bib66","doi-asserted-by":"crossref","first-page":"e122627","DOI":"10.1172\/jci.insight.122627","article-title":"Safety and tolerability of conditioning chemotherapy followed by CD19-targeted CAR T\u00a0cells for relapsed\/refractory CLL","volume":"5","author":"Geyer","year":"2019","journal-title":"JCI insight"},{"issue":"9","key":"10.1016\/j.hoc.2021.03.008_bib67","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1182\/blood-2015-11-679134","article-title":"Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia","volume":"127","author":"Fraietta","year":"2016","journal-title":"Blood"},{"issue":"Supplement_1","key":"10.1016\/j.hoc.2021.03.008_bib68","doi-asserted-by":"crossref","first-page":"4298","DOI":"10.1182\/blood-2019-127260","article-title":"Final results of phase 1, dose escalation study evaluating ARQ 531 in patients relapsed or refractory B-cell lymphoid malignancies","author":"Woyach","year":"2019","journal-title":"Blood"},{"issue":"10277","key":"10.1016\/j.hoc.2021.03.008_bib69","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/S0140-6736(21)00224-5","article-title":"Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1\/2 study","volume":"397","author":"Mato","year":"2021","journal-title":"Lancet"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S088985882100040X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S088985882100040X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:16:29Z","timestamp":1760184989000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S088985882100040X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":69,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["S088985882100040X"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2021.03.008","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of Chronic Lymphocytic Leukemia After Discontinuation of Bruton\u2019s Tyrosine Kinase Inhibitors","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2021.03.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}